Monday 21 September 2015, Amsterdam
The report, now available on ASDReports, recognizes the following companies as the key players in the Global GI Stool Testing Market: Quidel Corporation, Meridian Bioscience, Diasorin and Clinical Genomics
Other Prominent Vendors in the market are: Alere, Beckman Coulter, bioM?rieux, Bio-Rad Laboratories, CARE Products, Cenogenics, Exact Sciences, Epitope Diagnostic, Epigenomics, EIKEN CHEMICAL, Helena Laboratories, Hemosure, Mobidiag, Orion Diagnostica, Pinnacle BioLabs, Polymedco, Propper Manufacturing, ScheBo Biotech, and Trinity Biotech.
Commenting on the report, an analyst said: “Point-of-care diagnostic tests for infectious diseases and cancer can be performed at or near the site of patient care. These tests offer patients timely access to care and treatment, reducing the overall probability of disease transmission.”
According to the report, many companies are expanding into emerging countries, such as India, China, and Brazil, as these economies have significant growth potential. The implementation of government initiatives to build healthcare infrastructure, increase healthcare budgets, and advance technology propel market growth in these countries.
Further, the report states that gastrointestinal stool tests face stiff competition from their alternatives. Stool tests such as FIT can sometimes give false positive or negative results during colorectal cancer screening. In comparison, colonoscopy and CT colonography tests provide accurate results. For this reason, many medical professionals prefer these procedures to stool tests for the detection of colorectal cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : firstname.lastname@example.org
back to News